TCR-T cells
Phase 1Cell therapy
TCR-T cells is one of 141 biologic programs targeting Lung Cancer. It is currently in Phase 1.
4
Indications
8
Total Trials
6
Active Trials
140
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
286 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Beyfortus
BeiGenePhase 2
Taxotere
AAvyxa
Phase 2
Braftovi
PfizerPhase 2
Erbitux
IImclone
Phase 2
Sutent
PfizerPhase 2
Alimta
SShawn Eagle
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Acute Myeloid Leukemia1 trial
Esophageal Adenocarcinoma1 trial
Lung Cancer1 trial
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT03778814·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing DCTY Biotech Co.,Ltd.